Metraipolis › archive › dc_2574c76e997e

The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors — Europe PMC PMID:39576826

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39576826
DOI
10.1371/journal.pone.0312806
License (as archived)
CC0-1.0
Archived
2026-10-10T01:26:13.594Z
SHA-256 of the archived text
735ee068e5ded5c7261c3c9f9dadd057a3fc662836dbec3f2033f72401a5a879
Stable URL of this page
https://metraipolis.com/documento/dc_2574c76e997e

How to cite

The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors — Europe PMC PMID:39576826 — Europe PMC (en), https://europepmc.org/article/MED/39576826 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2574c76e997e (Metraipolis archive dc_2574c76e997e, sha256 735ee068e5ded5c7261c3c9f9dadd057a3fc662836dbec3f2033f72401a5a879)
BibTeX
@misc{dc2574c76e997e,
  title = {The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors — Europe PMC PMID:39576826},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39576826},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2574c76e997e; sha256 735ee068e5ded5c7261c3c9f9dadd057a3fc662836dbec3f2033f72401a5a879},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39576826. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The ALK5 (TGFBR1) receptor serine/threonine kinase transduces TGF-β (Transforming Growth Factor beta) signaling to activate SMAD2/3-dependent and -independent pathways. Here, we aimed to determine the functional consequences of ALK5 mutations in human endometrial cancer (EC). Somatic mutation data were retrieved from publicly available databases. Using seven in silico algorithms, 78.5% (11 of 14) of ALK5 kinase domain mutations in EC, including A230V-ALK5, were predicted to impact protein function. For in vitro studies, we focused on A230V-ALK5 because it was the only mutated residue located within the ATP-binding pocket, which is an important region for both ATP-binding and binding of ATP-competitive inhibitors. Constructs expressing wildtype-, constitutively-active-, kinase-dead-, or mutant A230V-ALK5, were transfected into NIH/3T3 cells. Following TGF-β1 stimulation, transient exogenous expression of A230V-ALK5 resulted in attenuated SMAD2/3 signal transduction and reduced AKT activation. We further showed that the A230V-ALK5 mutant had reduced stability resulting from increased ubiquitin-dependent protein degradation. Our structural modeling predicted that SB-431542, a small molecule ATP-competitive inhibitor of ALK5, binds to the A230V-ALK5 mutant with reduced affinity compared to wildtype-ALK5. We therefore examined the inhibitory effect of SB-431542 and galunisertib on wildtype- and mutant-ALK5 activity using a Smad-binding element (SBE) luciferase reporter assay combined with TGF-β1 stimulation, in NIH/3T3 cells and HEC-265 EC cells. SBE luciferase activity in A230V-ALK5 transfected cells was inhibited less by SB-431542 and galunisertib than in wildtype-ALK5 transfected cells indicating that A230V-ALK5 is less sensitive to inhibition by these agents than wildtype-ALK5, potentially due to changes in SB-431542/A230V-ALK5 binding affinity. Our findings are novel and show that A230V-ALK5 is a partial loss-of-function mutant that attenuates TGF-β1 signal transduction and has reduced sensitivity to ALK5 small molecule inhibitors.

Tema degli esploratori: scienze della vita e salute (ricerca Europe PMC «molecular biology», solo open access).
Pubblicazione: PloS one, 2024 (prima pubblicazione 2024-11-22).
Identificativi: PMID 39576826 · PMCID PMC11584080 · DOI 10.1371/journal.pone.0312806.
Descrittori MeSH principali: Endometrial Neoplasms; Receptors, Transforming Growth Factor beta; Signal Transduction; Receptor, Transforming Growth Factor-beta Type I; Protein Serine-Threonine Kinases.
Pagina: https://europepmc.org/article/MED/39576826 — https://doi.org/10.1371/journal.pone.0312806. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-10T00:55:33.650Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.